ArticleThe Journal of experimental medicine1991
Role of human decay-accelerating factor in the evasion of Schistosoma mansoni from the complement-mediated killing in vitro.
Article in The Journal of experimental medicine, 1991. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 50 citations in OpenAlex.
- Hidden in plain sight: How helminths manage to thrive in host blood.Frontiers in parasitology · 2023Review
- Schistosome immunomodulators.PLoS pathogens · 2021Review
- Transcriptome of the parasitic flatworm Schistosoma mansoni during intra-mammalian development.PLoS neglected tropical diseases · 2020Article
- Behind Enemy Lines: Immunomodulatory Armamentarium of the Schistosome Parasite.Frontiers in immunology · 2020Review
- Complement Evasion: An Effective Strategy That Parasites Utilize to Survive in the Host.Frontiers in microbiology · 2019Review
- How schistosomes alter the human serum proteome.Molecular and biochemical parasitology · 2017Article
- On the three-finger protein domain fold and CD59-like proteins in Schistosoma mansoni.PLoS neglected tropical diseases · 2013Article
- The emerging role of complement lectin pathway in trypanosomatids: molecular bases in activation, genetic deficiencies, susceptibility to infection, and complement system-based therapeutics.TheScientificWorldJournal · 2013Review
- Complement C2 receptor inhibitor trispanning: from man to schistosome.Springer seminars in immunopathology · 2005Review
- Receptor for Fc on the surfaces of schistosomes.Infection and immunity · 2001Article
- Acquired resistance of Escherichia coli to complement lysis by binding of glycophosphoinositol-anchored protectin (CD59).Infection and immunity · 1998Article
- Complement-related proteins in pathogenic organisms.Springer seminars in immunopathology · 1994Review
- Membrane proteins that protect against complement lysis.Springer seminars in immunopathology · 1994Review
Corrections and comments
- Erratum issuedFatima M [corrected to Horta MF]
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Decay-accelerating factor (DAF) is a 70-kD membrane glycoprotein that prevents complement (C)-mediated hemolysis by blocking the assembly or accelerating the decay of C3 convertase. Purified DAF is known to incorporate into the membrane of DAF-deficient cells, inhibiting lysis. Since Schistosoma mansoni is a blood-dwelling parasite, we investigated whether DAF can be transferred from human erythrocytes to the worm and protect it against C-mediated killing in vitro. We have found that schistosomula (schla) incubated with normal human erythrocytes (N-HuE), but not with DAF-deficient erythrocytes, become resistant to C damage in vitro. Protected parasites acquire a 70-kD surface protein which can be immunoprecipitated by anti-DAF antibodies. The acquired resistance is abrogated by treatment of N-HuE-incubated parasites with anti-DAF antibody. These results indicate that, in vitro, N-HuE DAF can be transferred to schla, and suggest its participation in preventing their C-mediated killing. This could represent an important strategy of parasites to evade the host's immune response in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.